Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 1/20 | 0.43 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.41 |
| ▸ | SLC5A2 | P31639 | 1/20 | 0.41 |
| ▸ | FLT3 | P36888 | 12/20 | 0.37 |
| ▸ | DHFR | P00374 | 1/20 | 0.34 |
| ▸ | DCPS | Q96C86 | 1/20 | 0.34 |
| ▸ | CACNA1H | O95180 | 2/20 | 0.34 |
| ▸ | CACNA1G | O43497 | 1/20 | 0.34 |
| ▸ | CACNA1I | Q9P0X4 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.33 |
| ▸ | BACE1 | P56817 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13651823 | 0.83 | MAPT (0.39) | — | |
| SCHEMBL9935890 | 0.82 | ACACB (0.50) | ACACBSLC5A1SLC5A2FLT3DHFR | |
| SCHEMBL13183274 | 0.81 | NQO1 (0.47) | ACACB | |
| SCHEMBL12855817 | 0.80 | ESR1 (0.31) | ACACB | |
| SCHEMBL13651821 | 0.79 | ALDH1A1 (0.36) | — | |
| SCHEMBL4806456 | 0.79 | NPC1 (0.48) | — | |
| SCHEMBL10329404 | 0.79 | OPRM1 (0.43) | — | |
| SCHEMBL13651779 | 0.79 | ALDH1A1 (0.49) | — | |
| SCHEMBL10329399 | 0.79 | ALDH1A1 (0.36) | DHFRDCPS | |
| SCHEMBL10329392 | 0.78 | ALDH1A1 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2298753-B1 | Novel oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORP (JP) | 2015-07-08 | — | — | EP | disclosed |
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| US-8222436-B2 | Oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | FUJIFILM CORPORATION (JP) | 2012-07-17 | — | — | US | disclosed |
| EP-2298753-A1 | Novel oxetane compound, active energy ray-curable composition, active energy ray-curable ink composition and inkjet recording method | Fujifilm Corporation (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | FUJIFILM CORPORATION (JP) | 2011-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110052831-A1 | NOVEL OXETANE COMPOUND, ACTIVE ENERGY RAY-CURABLE COMPOSITION, ACTIVE ENERGY RAY-CURABLE INK COMPOSITION AND INKJET RECORDING METHOD | OXER1, NOX1, NOX4 | ACACB 2666/4885SLC5A1 1207/4885SLC5A2 2542/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.